E7-Targeted Nanotherapeutics for Key HPV Afflicted Cervical Lesions by Employing CRISPR/Cas9 and Poly (Beta-Amino Ester)

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. doi:10.1002/ijc.29210
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–e203. doi:10.1016/S2214-109X(19)30482-6
   PubMed Web of Science ®Google Scholar
• Francis SA, Nelson J, Liverpool J, Soogun S, Mofammere N, Thorpe RJ. Examining attitudes and knowledge about HPV and cervical cancer risk among female clinic attendees in Johannesburg, South Africa. Vaccine. 2010;28(50):8026–8032. doi:10.1016/j.vaccine.2010.08.090
   PubMed Web of Science ®Google Scholar
• Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88(1):63–73. doi:10.1038/sj.bjc.6600688
   PubMed Web of Science ®Google Scholar
• Bosch FX, de Sanjose S. Chapter 1: human papillomavirus and cervical cancer–burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;1(31):3–13. doi:10.1093/oxfordjournals.jncimonographs.a003479
   Google Scholar
• Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10(8):550–560. doi:10.1038/nrc2886
   PubMed Web of Science ®Google Scholar
• Taghizadeh E, Jahangiri S, Rostami D, et al. Roles of E6 and E7 Human Papillomavirus Proteins in Molecular Pathogenesis of Cervical Cancer. Curr Protein Pept Sci. 2019;20(9):926–934. doi:10.2174/1389203720666190618101441
   PubMedGoogle Scholar
• Pett M, Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol. 2007;212(4):356–367. doi:10.1002/path.2192
   PubMed Web of Science ®Google Scholar
• Hu Z, Zhu D, Wang W, et al. Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism. Nat Genet. 2015;47(2):158–163. doi:10.1038/ng.3178
   PubMed Web of Science ®Google Scholar
• Pal A, Kundu R. Human Papillomavirus E6 and E7: the Cervical Cancer Hallmarks and Targets for Therapy. Front Microbiol. 2019;10:3116. doi:10.3389/fmicb.2019.03116
   PubMed Web of Science ®Google Scholar
• Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection - A randomized trial. JAMA-J Am Med Assoc. 2007;298(7):743–753. doi:10.1001/jama.298.7.743
   PubMed Web of Science ®Google Scholar
• Ciavattini A, Clemente N, Carpini GD, et al. Loop electrosurgical excision procedure and risk of miscarriage. Fertil Steril. 2015;103(4):1043–1048. doi:10.1016/j.fertnstert.2014.12.112
   PubMed Web of Science ®Google Scholar
• Pahle J, Walther W. Vectors and strategies for nonviral cancer gene therapy. Expert Opin Biol Ther. 2016;16(4):443–461. doi:10.1517/14712598.2016.1134480
   PubMed Web of Science ®Google Scholar
• Zhang J, Ding M, Xu K, Mao L, Zheng J. shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy. Oncotarget. 2016;7(20):29824–29834. doi:10.18632/oncotarget.8035
   PubMedGoogle Scholar
• Dominguez AA, Lim WA, Qi LS. Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation. Nat Rev Mol Cell Biol. 2016;17(1):5–15. doi:10.1038/nrm.2015.2
   PubMed Web of Science ®Google Scholar
• Almeida AM, Queiroz JA, Sousa F, Sousa A. Cervical cancer and HPV infection: ongoing therapeutic research to counteract the action of E6 and E7 oncoproteins. Drug Discov Today. 2019;24(10):2044–2057. doi:10.1016/j.drudis.2019.07.011
   PubMed Web of Science ®Google Scholar
• Evers B, Jastrzebski K, Heijmans JP, Grernrum W, Beijersbergen RL, Bernards R. CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes. Nat Biotechnol. 2016;34(6):631–633. doi:10.1038/nbt.3536
   PubMed Web of Science ®Google Scholar
• Chen M, Mao A, Xu M, Weng Q, Mao J, Ji J. CRISPR-Cas9 for cancer therapy: opportunities and challenges. Cancer Lett. 2019;447:48–55. doi:10.1016/j.canlet.2019.01.017
   PubMed Web of Science ®Google Scholar
• Song X, Liu C, Wang N, et al. Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy. Adv Drug Deliv Rev. 2021;168:158–180. doi:10.1016/j.addr.2020.04.010
   PubMed Web of Science ®Google Scholar
• Sharma G, Sharma AR, Bhattacharya M, Lee SS. Chakraborty C. CRISPR-Cas9: a Preclinical and Clinical Perspective for the Treatment of Human Diseases. Mol Ther. 2021;29(2):571–586. doi:10.1016/j.ymthe.2020.09.028
   PubMedGoogle Scholar
• Xiao B, Laroui H, Viennois E, et al. Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology. 2014;146(5):1289–300 e1-19. doi:10.1053/j.gastro.2014.01.056
   PubMed Web of Science ®Google Scholar
• Xu CF, Chen GJ, Luo YL, et al. Rational designs of in vivo CRISPR-Cas delivery systems. Adv Drug Deliv Rev. 2021;168:3–29. doi:10.1016/j.addr.2019.11.005
   PubMed Web of Science ®Google Scholar
• Weber W, Fussenegger M. Pharmacologic transgene control systems for gene therapy. J Gene Med. 2006;8(5):535–556. doi:10.1002/jgm.903
   PubMedGoogle Scholar
• Zhou Z, Liu X, Zhu D, et al. Nonviral cancer gene therapy: delivery cascade and vector nanoproperty integration. Adv Drug Deliv Rev. 2017;115:115–154. doi:10.1016/j.addr.2017.07.021
   PubMed Web of Science ®Google Scholar
• Li J, Roise JJ, He M, Das R, Murthy N. Non-viral strategies for delivering genome editing enzymes. Adv Drug Deliv Rev. 2021;168:99–117. doi:10.1016/j.addr.2020.09.004
   PubMed Web of Science ®Google Scholar
• Ma K, Mi CL, Cao XX, Wang TY. Progress of cationic gene delivery reagents for non-viral vector. Appl Microbiol Biotechnol. 2021;105(2):525–538. doi:10.1007/s00253-020-11028-6
   PubMedGoogle Scholar
• Wang DY, Yang G, van der Mei HC, Ren Y, Busscher HJ, Shi L. Liposomes with Water as a pH-Responsive Functionality for Targeting of Acidic Tumor and Infection Sites. Angew Chem Int Ed Engl. 2021;60(32):17714–17719. doi:10.1002/anie.202106329
   PubMedGoogle Scholar
• Radmanesh F, Sadeghi Abandansari H, Ghanian MH, et al. Hydrogel-mediated delivery of microRNA-92a inhibitor polyplex nanoparticles induces localized angiogenesis. Angiogenesis. 2021;24(3):657–676. doi:10.1007/s10456-021-09778-6
   PubMedGoogle Scholar
• Zhu D, Shen H, Tan S, et al. Nanoparticles Based on Poly (beta-Amino Ester) and HPV16-Targeting CRISPR/shRNA as Potential Drugs for HPV16-Related Cervical Malignancy. Mol Ther. 2018;26(10):2443–2455. doi:10.1016/j.ymthe.2018.07.019
   PubMed Web of Science ®Google Scholar
• Zhang H, Li J, Yuan R, et al. Augment the efficacy of eradicating metastatic lesions and tumor proliferation in breast cancer by honokiol-loaded pH-sensitive targeted lipid nanoparticles. Colloids Surf B Biointerfaces. 2021;207:112008. doi:10.1016/j.colsurfb.2021.112008
   PubMed Web of Science ®Google Scholar
• Guerrero-Cazares H, Tzeng SY, Young NP, Abutaleb AO, Quinones-Hinojosa A, Green JJ. Biodegradable Polymeric Nanoparticles Show High Efficacy and Specificity at DNA Delivery to Human Glioblastoma in Vitro and in Vivo. Acs Nano. 2014;8(5):5141–5153. doi:10.1021/nn501197v
   PubMed Web of Science ®Google Scholar
• Tzeng SY, Higgins LJ, Pomper MG, Green JJ. Student award winner in the Ph.D. category for the 2013 society for biomaterials annual meeting and exposition, April 10–13, 2013, Boston, Massachusetts: biomaterial-mediated cancer-specific DNA delivery to liver cell cultures using synthetic poly(beta-amino ester)s. J Biomed Mater Res A. 2013;101(7):1837–1845. doi:10.1002/jbm.a.34616
   PubMed Web of Science ®Google Scholar
• Kim J, Kang Y, Tzeng SY, Green JJ. Synthesis and application of poly(ethylene glycol)-co-poly(beta-amino ester) copolymers for small cell lung cancer gene therapy. Acta Biomater. 2016;41:293–301. doi:10.1016/j.actbio.2016.05.040
   PubMed Web of Science ®Google Scholar
• Kaczmarek JC, Patel AK, Rhym LH, et al. Systemic delivery of mRNA and DNA to the lung using polymer-lipid nanoparticles. Biomaterials. 2021;275:120966. doi:10.1016/j.biomaterials.2021.120966
   PubMed Web of Science ®Google Scholar
• Guo R, Li K, Tian B, et al. Elaboration on the architecture of pH-sensitive surface charge-adaptive micelles with enhanced penetration and bactericidal activity in biofilms. J Nanobiotechnology. 2021;19(1):232. doi:10.1186/s12951-021-00980-8
   PubMed Web of Science ®Google Scholar
• Bechtold V, Beard P, Raj K. Human papillomavirus type 16 E2 protein has no effect on transcription from episomal viral DNA. J Virol. 2003;77(3):2021–2028. doi:10.1128/Jvi.77.3.2021-2028.2003
   PubMedGoogle Scholar
• Kamat CD, Shmueli RB, Connis N, Rudin CM, Green JJ, Hann CL. Poly(beta-amino ester) Nanoparticle Delivery of TP53 Has Activity against Small Cell Lung Cancer In Vitro and In Vivo. Mol Cancer Ther. 2013;12(4):405–415. doi:10.1158/1535-7163.Mct-12-0956
   PubMedGoogle Scholar
• Anderson DG, Peng WD, Akinc A, et al. A polymer library approach to suicide gene therapy for cancer. P Natl Acad Sci USA. 2004;101(45):16028–16033. doi:10.1073/pnas.0407218101
   PubMedGoogle Scholar
• Sudenga SL, Shrestha S. Key considerations and current perspectives of epidemiological studies on human papillomavirus persistence, the intermediate phenotype to cervical cancer. Int J Infect Dis. 2013;17(4):e216–20. doi:10.1016/j.ijid.2012.12.027
   PubMed Web of Science ®Google Scholar
• Elfstrom KM, Arnheim-Dahlstrom L, von Karsa L, Dillner J. Cervical cancer screening in Europe: quality assurance and organisation of programmes. Eur J Cancer. 2015;51(8):950–968. doi:10.1016/j.ejca.2015.03.008
   PubMed Web of Science ®Google Scholar
• Goldhaber-Fiebert JD, Goldie SJ. Estimating the cost of cervical cancer screening in five developing countries. Cost Eff Resour Alloc. 2006;4:13. doi:10.1186/1478-7547-4-13
   PubMedGoogle Scholar
• Campos NG, Sharma M, Clark A, Kim JJ, Resch SC. Resources Required for Cervical Cancer Prevention in Low- and Middle-Income Countries. PLoS One. 2016;11(10):e0164000. doi:10.1371/journal.pone.0164000
   PubMedGoogle Scholar
• Kirkegaard P, Gustafson LW, Petersen LK, Andersen B. ‘I Want the Whole Package’. Elderly Patients’ Preferences for Follow-Up After Abnormal Cervical Test Results: a Qualitative Study. Patient Prefer Adherence. 2020;14:1185–1193. doi:10.2147/PPA.S259095
   PubMed Web of Science ®Google Scholar
• Gilham C, Crosbie EJ, Peto J. Cervical cancer screening in older women. BMJ. 2021;372:n280. doi:10.1136/bmj.n280
   PubMedGoogle Scholar
• Jonson AL, Rogers LM, Ramakrishnan S, Downs LS Jr. Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer. Gynecol Oncol. 2008;111(2):356–364. doi:10.1016/j.ygyno.2008.06.033
   PubMedGoogle Scholar
• Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature. 2009;457(7228):426–433. doi:10.1038/nature07758
   PubMed Web of Science ®Google Scholar
• Kim J, Sunshine JC, Green JJ. Differential Polymer Structure Tunes Mechanism of Cellular Uptake and Transfection Routes of Poly(beta-amino ester) Polyplexes in Human Breast Cancer Cells. Bioconjugate Chem. 2014;25(1):43–51. doi:10.1021/bc4002322
   PubMedGoogle Scholar
• Mastorakos P, da Silva AL, Chisholm J, et al. Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy. Proc Natl Acad Sci U S A. 2015;112(28):8720–8725. doi:10.1073/pnas.1502281112
   PubMed Web of Science ®Google Scholar
• Min S, Jin Y, Hou CY, et al. Bacterial tRNase-Based Gene Therapy with Poly(beta-Amino Ester) Nanoparticles for Suppressing Melanoma Tumor Growth and Relapse. Adv Healthc Mater. 2018;7(16):e1800052. doi:10.1002/adhm.201800052
   PubMedGoogle Scholar
• Jung HS, Rajasekaran N, Ju W, Shin YK. Human Papillomavirus: current and Future RNAi Therapeutic Strategies for Cervical Cancer. J Clin Med. 2015;4(5):1126–1155. doi:10.3390/jcm4051126
   PubMedGoogle Scholar
• Chen Z, Liu F, Chen Y, et al. Targeted Delivery of CRISPR/Cas9-Mediated Cancer Gene Therapy via Liposome-Templated Hydrogel Nanoparticles. Adv Funct Mater. 2017;27:46. doi:10.1002/adfm.201703036
   Google Scholar
• Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, Saltzman WM. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater. 2009;8(6):526–533. doi:10.1038/nmat2444
   PubMed Web of Science ®Google Scholar
• Jones CH, Chen M, Ravikrishnan A, et al. Mannosylated poly(beta-amino esters) for targeted antigen presenting cell immune modulation. Biomaterials. 2015;37:333–344. doi:10.1016/j.biomaterials.2014.10.037
   PubMed Web of Science ®Google Scholar
• Yang F, Cho SW, Son SM, et al. Genetic engineering of human stem cells for enhanced angiogenesis using biodegradable polymeric nanoparticles. Proc Natl Acad Sci U S A. 2010;107(8):3317–3322. doi:10.1073/pnas.0905432106
   PubMed Web of Science ®Google Scholar
• Palmeira-de-oliveira R, Palmeira-de-oliveira A, Martinez-de-oliveira J. New strategies for local treatment of vaginal infections. Adv Drug Deliv Rev. 2015;92:105–122. doi:10.1016/j.addr.2015.06.008
   PubMed Web of Science ®Google Scholar
• Moon SB, Kim DY, Ko JH, Kim YS. Recent advances in the CRISPR genome editing tool set. Exp Mol Med. 2019;51(11):1–11. doi:10.1038/s12276-019-0339-7
   Google Scholar
• Kumar A, Rathi E, Hariharapura RC, Kini SG. Is viral E6 oncoprotein a viable target? A critical analysis in the context of cervical cancer. Med Res Rev. 2020;40(5):2019–2048. doi:10.1002/med.21697
   PubMed Web of Science ®Google Scholar
• Kamal M, Lameiras S, Deloger M, et al. Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site. Br J Cancer. 2021;124(4):777–785. doi:10.1038/s41416-020-01153-4
   PubMedGoogle Scholar
• Baumann A, Henriques J, Selmani Z, et al. HPV16 Load Is a Potential Biomarker to Predict Risk of High-Grade Cervical Lesions in High-Risk HPV-Infected Women: a Large Longitudinal French Hospital-Based Cohort Study. Cancers. 2021;13:16. doi:10.3390/cancers13164149
   Google Scholar